Tas-102

Bladder Cancer

National Cancer Institute (NCI)unclassifiedPhase 2Active

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 73/ 100

Competitive context

97 Active assets in the Bladder Cancer cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II G1 Therapeutics, Inc.	Phase 3	BBB
Carboplatin G1 Therapeutics, Inc.	Phase 3	BB
Pembrolizumab Essen Biotech	Phase 3	BB
Cyclophosphamide Beijing Biotech	Phase 3	BB
VINBLASTINE University of Southern California	Phase 3	BB

View all 50 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant

BB

Indicative ·

68 / 100

Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant

BB

Indicative ·

68 / 100

Carcinoma, Islet CellDormant

BB

Indicative ·

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.